Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Granulysin: a novel antimicrobial.

J Kumar1, S Okada, C Clayberger

  • 1Department of Medicine, Division of Nephrology, Stanford University, Stanford, CA 94305, USA.

Expert Opinion on Investigational Drugs
|February 15, 2001
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Dengue and Typhoid: A Duet of Choreoathetosis.

Cureus·2024
Same author

Cavernous Angioma: A Rare Cause of Multiple Cranial Nerve Palsies.

Cureus·2024
Same author

Search for Rare b→dℓ^{+}ℓ^{-} Transitions at Belle.

Physical review letters·2024
Same author

Whitmore's Disease: A Case Report of Melioidosis Triggering Hemophagocytic Lymphohistiocytosis.

Cureus·2024
Same author

Discoloration and Dilemma: A Case Report of Hand-Foot Syndrome Associated With Capecitabine Use.

Cureus·2024
Same author

Antibodies in Aseptic Meningitis of Connective Tissue Disorder: A Case Report.

Cureus·2024
Same journal

Advancements in longevity pharmacology research - are we finally seeing clinical progression?

Expert opinion on investigational drugs·2026
Same journal

Consideration of the use of nalbuphine in idiopathic pulmonary fibrosis-associated cough: to cough or not to cough so much?

Expert opinion on investigational drugs·2026
Same journal

Investigational new drug TAP-1502 beginning clinical study for seborrheic dermatitis.

Expert opinion on investigational drugs·2026
Same journal

Cannabinoid use in adults with sickle cell disease: therapeutic development and clinical insights.

Expert opinion on investigational drugs·2026
Same journal

Odronextamab: a bispecific antibody for follicular lymphoma.

Expert opinion on investigational drugs·2026
Same journal

Evaluating the investigational drug landscape for <i>ESR1</i>-mutated, estrogen receptor-positive, HER2-negative metastatic breast cancer.

Expert opinion on investigational drugs·2026
See all related articles

Granulysin, a novel molecule from human immune cells, shows broad antimicrobial activity. Synthetic granulysin peptides demonstrate selective bacteria-killing potential for new antibiotic development.

Area of Science:

  • Immunology
  • Microbiology
  • Molecular Biology

Background:

  • Granulysin is a cytotoxic molecule produced by human cytolytic T-lymphocytes (CTLs) and natural killer (NK) cells.
  • It exhibits activity against a wide spectrum of microbes, including bacteria, parasites, and Mycobacterium tuberculosis.
  • Granulysin is functionally related to other antimicrobial peptides but possesses a distinct structure.

Purpose of the Study:

  • To investigate the antimicrobial properties of granulysin.
  • To explore the structural relationships of granulysin with other known lytic molecules.
  • To assess the potential therapeutic applications of synthetic granulysin-derived peptides as novel antibiotics.

Main Methods:

  • Analysis of granulysin's antimicrobial spectrum.

Related Experiment Videos

  • Structural comparison with related peptides like defensins, magainins, porcine NK-lysin, and amoebapores.
  • Synthesis and evaluation of granulysin-derived peptides for selective activity against microbial and eukaryotic cells.

    • Main Results:

    • Granulysin demonstrates broad-spectrum antimicrobial activity.
    • Structural similarities were identified with porcine NK-lysin and amoebapores.
    • Synthetic granulysin peptides exhibited differential activity, with some showing selective bactericidal effects.

    Conclusions:

    • Granulysin is a potent antimicrobial agent produced by human immune cells.
    • Its unique structure and broad activity profile make it a promising candidate for therapeutic development.
    • Selective bactericidal peptides derived from granulysin represent a potential new class of antibiotics.